The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …

Purpose To review the impact of collaborative studies on advances in the biology and
treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A …

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. In the past
ALL was intractable but now the survival probability is as high as 80–90%. Improved …

Monitoring of minimal residual disease (MRD) has become routine clinical practice in
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk
subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …